| 摘要 |
<p>This invention is related to the use of at least one oligonucleotide with a length of from about 8 to about 30 nucleotide building blocks for manufacturing a pharmaceutical preparation for the prophylaxis and/or the treatment of diseases, that are modulated by TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos, and/or prostaglandin E2 in a mammal, in particular for the treatment of cancer, metastases, disease of the nervous system or immunosuppression, wherein said oligonucleotide hybridizes with a messenger RNA of a TGF-beta2, TGF-betal, TGF-beta3, VEGF, interleukin- 10, c-jun, c-fos and/or prostaglandin E2 gene and wherein said preparation comprises said oligonucleotide in a concentration of about 1 microM to about 25 microM.</p> |
